133
Views
2
CrossRef citations to date
0
Altmetric
Araştırmalar/Original Papers

Comparison of Polypharmacy in Schizophrenia and Other Psychotic Disorders in Outpatient and Inpatient Treatment Periods: A Naturalistic One Year Follow-up Study

Şizofreni ve diğer psikotik bozukluklarda çoklu antipsikotik ilaç kullanımının yatış ve ayaktan izlem dönemlerinde karşılaştırılması: Bir yıllık doğal izlem çalışması

, M.D., , M.D., , M.D., , M.D., , M.D., , M.D. & show all
Pages 130-138 | Received 22 Nov 2011, Accepted 19 Apr 2012, Published online: 08 Nov 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mesut Cetin. (2013) Asenapine: A Novel Hope in the Treatment of Schizophrenia and Manic and Mixed Episodes of Bipolar I Disorder. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 23:1, pages 99-106.
Read now

Articles from other publishers (1)

Priti P. Pednekar, Tamás Ágh, Maria Malmenäs, Amit D. Raval, Bryan M. Bennett, Bijan J. Borah, David S. Hutchins, Elizabeth Manias, Allison F. Williams, Mickaël Hiligsmann, Adina Turcu-Stiolica, John E. Zeber, Lusine Abrahamyan, Thomas J. Bunz & Andrew M. Peterson. (2019) Methods for Measuring Multiple Medication Adherence: A Systematic Review–Report of the ISPOR Medication Adherence and Persistence Special Interest Group. Value in Health 22:2, pages 139-156.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.